Physician profile
Daniel J Hansen
NPI 1114121217
$4,478.16
in general payments reported to CMS, 2019-2025
31 companies · $535 in 2025
The $535 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $795 · 2020: $648 · 2021: $841 · 2022: $565 · 2023: $679 · 2024: $417 · 2025: $535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,531 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,530.95 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,076.61 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $354.12 | 2019-2025 | |
| Leo Pharma INC. | $338.15 | 2021-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $309.29 | 2019-2025 | Tremfya, Remicade, Stelara |
| Pfizer INC. | $287.68 | 2019-2021 | |
| Genzyme Corporation | $245.27 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $184.58 | 2022-2025 | Sotyktu |
| Biofrontera INC. | $147.84 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Galderma Laboratories, L.P. | $145.24 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $142.36 | 2019-2025 | Absorica Ld, Winlevi |
| Helsinn Therapeutics (U.S.), INC. | $132.66 | 2019-2025 | Valchlor |
| Regeneron Healthcare Solutions, INC. | $131.37 | 2020-2022 | |
| Amgen INC. | $128.88 | 2019-2024 | Otezla |
| Sanofi-Aventis U.S. LLC | $111.76 | 2019-2020 | |
| Genentech USA, INC. | $98.14 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $90.91 | 2019-2023 | Taltz, Olumiant |
| Vyne Pharmaceuticals INC. | $86.06 | 2020-2021 | |
| Allergan, INC. | $71.56 | 2020-2021 | |
| Melinta Therapeutics, LLC | $65.87 | 2019 | |
| Boston Scientific Corporation | $59.95 | 2019-2021 | |
| Dermira, INC. | $49.35 | 2020-2021 | |
| Ucb, INC. | $45.41 | 2019-2020 | |
| Arcutis Biotherapeutics, INC. | $42.39 | 2023 | |
| Dermavant Sciences, INC. | $30.72 | 2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $26.97 | 2019-2020 | |
| Celgene Corporation | $19.82 | 2019 | |
| Stryker Corporation | $15.94 | 2025 | Ortholoc 2 Lapifuse |
| Treace Medical Concepts, INC. | $15.74 | 2022 | |
| Mylan Pharmaceuticals INC. | $12.02 | 2019 | |
| Organon LLC | $7.80 | 2025 | Nexplanon |
| Prugen, INC. Pharmaceuticals | $3.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Hansen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.